Search bioRxiv⌕ Search

Biology subjects

Alural, B.

Publications and source records attributed to Alural, B..

2 recordsLinked to original sources

Preclinical Study of Cannflavins A and B Action Against Glioblastoma Cells

AO_SCPLOWBSTRACTC_SCPLOWO_ST_ABSBackgroundC_ST_ABSFlavonoids represent a large group of naturally occurring polyphenolic compounds, many of which have been found to produce valuable biological outcomes, including action against cancer cells. Glioblastoma multiforme (GBM) is an aggressive type of brain tumor that is associated with a poor prognosis and has limited treatment options. Previous findings suggest that cannflavins can produce promising effects for pancreatic and bladder cancers, but the efficacy of these phytochemicals in attacking brain tumour cells remains unknown. Our study evaluates the potential of cannflavin A and cannflavin B against GBM cells using a range of in vitro approaches. ResultsWe conducted experiments using A-172 and U-87 GBM lines to assess the impact of cannflavins A and B on cell viability, cycle, migration, and invasion capacity. Our results revealed a consistent dose-dependent decrease in cell viability in both lines after the addition of cannflavin B to the culture media. Interestingly, we found that chrysoeriol (the non-prenylated synthesis precursor of cannflavins in the Cannabis sativa plant) only has a limited adverse effect on survival using the same approach, while techtochrysin (an O-methylated flavone) has none. Using time-lapse live-cell imaging and a scratch assay, we also show that cannflavins can inhibit tumor cell migration at concentrations below those that produce significant cell death. Finally, we found that cannflavin B exhibits anti-migratory and anti-invasive properties in transwell and tumorsphere assays, underscoring its multifaceted therapeutic potential. ConclusionThese findings suggest that cannflavin B holds promise as a therapeutic agent in the treatment of GBM. HO_SCPLOWIGHLIGHTSC_SCPLOWO_LICannflavin B but not cannflavin A limits the viability of A-172 and U-87 GBM cells in a concentration- and time-dependent manner. C_LIO_LIUsing time-lapse live-cell imaging and a scratch assay, we provide evidence that cannflavins A and B can inhibit GBM cell migration at concentrations below those that result in a significant reduction in cell viability. C_LIO_LICannflavin B exhibits robust anti-migratory and anti-invasive properties in transwell and tumorsphere assays, underscoring its multifaceted therapeutic potential. C_LIO_LIAlthough previous work had reported the capacity of cannflavins A and B to interfere with TrkB and downstream the MAPK/AKT signaling pathways in mouse primary neurons, the effect of those molecules is limited in GBMs, suggesting that other targets are engaged to produce the cellular effects. C_LI

pharmacology and toxicology↗

Interference of Neuronal TrkB Signaling by the Cannabis-Derived Flavonoids Cannflavins A and B

Cannflavins A and B are flavonoids that accumulate in the Cannabis sativa plant. These specialized metabolites are uniquely prenylated and highly lipophilic, which, a priori, may permit their interaction with membrane-bound enzymes and receptors. Although previous studies found that cannflavins can produce anti-inflammatory responses by inhibiting the biosynthesis of pro- inflammatory mediators, the full extent of their cellular influence remains to be understood. Here, we studied these flavonoids in relation to the Tropomyosin receptor kinase B (TrkB), a receptor tyrosine kinase that is activated by the growth factor brain-derived neurotrophic factor (BDNF). Using mouse primary cortical neurons, we first collected evidence that cannflavins prevent the accumulation of Activity-regulated cytoskeleton-associated (Arc, also known as Arg3.1) protein upon TrkB stimulation by exogenous BDNF in these cells. Consistent with this effect, we also observed a reduced activation of TrkB and downstream signaling effectors that mediate Arc mRNA transcription when BDNF was co-applied with the cannflavins. Of note, we also performed a high-throughput screen that demonstrated a lack of agonist action of cannflavins towards 320 different G protein-coupled receptors, a result that specifically limit the possibility of a TrkB transinactivation scenario via G protein signaling to explain our results with dissociated neurons. Finally, we used Neuro2a cells overexpressing TrkB to show that cannflavins can block the growth of neurites and increased survival rate produced by the higher abundance of the receptor in this model. Taken together, our study offers a new path to understand the reported effects of cannflavins and other closely related compounds in different cellular contexts.

pharmacology and toxicology↗